Trial · NCT01163253
Adverse events634
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 634
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Tofacitinib 10 mg | 73 | 2,281 | |
| other | Diarrhoea | Gastrointestinal disorders | Tofacitinib 5 mg or 10 mg | 32 | 586 | |
| other | Bronchitis | Infections and infestations | Tofacitinib 10 mg | 134 | 2,281 | |
| other | Bronchitis | Infections and infestations | Tofacitinib 5 mg or 10 mg | 48 | 586 | |
| other | Herpes zoster | Infections and infestations | Tofacitinib 10 mg | 136 | 2,281 | |
| other | Herpes zoster | Infections and infestations | Tofacitinib 5 mg or 10 mg | 33 | 586 | |
| other | Influenza | Infections and infestations | Tofacitinib 10 mg | 126 | 2,281 | |
| other | Influenza | Infections and infestations | Tofacitinib 5 mg or 10 mg | 23 | 586 | |
| other | Nasopharyngitis | Infections and infestations | Tofacitinib 10 mg | 476 | 2,281 | |
| other | Nasopharyngitis | Infections and infestations | Tofacitinib 5 mg or 10 mg | 122 | 586 | |
| other | Upper respiratory tract infection | Infections and infestations | Tofacitinib 10 mg | 264 | 2,281 | |
| other | Upper respiratory tract infection | Infections and infestations | Tofacitinib 5 mg or 10 mg | 51 | 586 | |
| other | Urinary tract infection | Infections and infestations | Tofacitinib 10 mg | 145 | 2,281 | |
| other | Urinary tract infection | Infections and infestations | Tofacitinib 5 mg or 10 mg | 42 | 586 | |
| other | Blood cholesterol increased | Investigations | Tofacitinib 10 mg | 86 | 2,281 | |
| other | Blood cholesterol increased | Investigations | Tofacitinib 5 mg or 10 mg | 33 | 586 | |
| other | Blood creatine phosphokinase increased | Investigations | Tofacitinib 10 mg | 294 | 2,281 | |
| other | Blood creatine phosphokinase increased | Investigations | Tofacitinib 5 mg or 10 mg | 92 | 586 | |
| other | Gamma-glutamyltransferase increased | Investigations | Tofacitinib 10 mg | 81 | 2,281 | |
| other | Gamma-glutamyltransferase increased | Investigations | Tofacitinib 5 mg or 10 mg | 38 | 586 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01163253/events